Related Experiment Video
Updated: Dec 11, 2025
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
17.4K
Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease
1Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Institute of Bioengineering, Guangdong Academy of Sciences, Guangzhou 510316, China.
Microorganisms
|August 23, 2020
Summary
Targeting the SARS-CoV-2 main protease (3CLpro) is crucial for developing new COVID-19 antivirals. Structural studies guide the design of potent protease inhibitors to block viral replication effectively.
Area of Science:
- Virology
- Drug Discovery
- Structural Biology
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, became a global pandemic requiring effective therapeutics beyond vaccines.
- The SARS-CoV-2 main protease (3CLpro/Mpro) is essential for viral replication, making it a prime target for antiviral drug development.
Purpose of the Study:
- To review structural studies on the SARS-CoV-2 main protease.
- To summarize strategies and available inhibitors for targeting this viral protease.
- To highlight the role of structure-guided drug design in developing COVID-19 antivirals.
Main Methods:
- Analysis of structural data for SARS-CoV-2 main protease.
- Review of inhibitor development strategies and existing compounds.
- Evaluation of structure-activity relationships for protease inhibitors.
Main Results:
- High-resolution structures of the main protease are available, facilitating rational drug design.
- Various strategies have been employed to develop inhibitors targeting the 3CLpro.
- Potent peptidic inhibitors and diverse compound scaffolds show promise for antiviral development.
Conclusions:
- Structure-guided drug design is a key strategy for developing effective SARS-CoV-2 antivirals.
- The development of potent protease inhibitors targeting 3CLpro is feasible and crucial for combating COVID-19.
